WARNER-LAMBERT REZULIN INSULIN RESISTANCE CLAIM IN PRESS RELEASE QUESTIONED BY FDA AD DIVISION; SB REPRINTS CLAIMING KYTRIL SUPERIORITY TO ZOFRAN ALSO CITED
Executive Summary
Warner-Lambert will provide FDA with data in support of its insulin resistance claim following a Feb. 24 correspondence from the Division of Drug Marketing, Advertising & Communications contending that the company made "false and misleading" statements in a press release regarding its oral antihyperglycemic agent Rezulin (troglitazone).